JenaValve appoints medtech veteran Drachman CEO
This article was originally published in Clinica
Executive Summary
German transcatheter aortic valve developer JenaValve has made David Drachman CEO, replacing Helmut Straubinger, who has headed up the company since 2006. Mr Drachman, who JenaValve hopes will help position it as “a significant player in the TAVI space,” has 30 years of experience in the cardiovascular medical device industry. Most recently, he was president and CEO of atrial fibrillation treatment specialist AtriCure from 2002 until September 2012. Before this, he was at Biosense Webster, which has since become part of Johnson & Johnson; and previously led Impulse Dynamics. Mr Drachman has also worked for Ventritex and Boston Scientific.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.